Lei Huo, MD, PhD

Peer-Reviewed Articles

1. Guirguis, MS, Adrada, BE, Yam, C, Tripathy, D, Candelaria, RP, Yang, W, Patel, MM, Moseley, T, Perez, F, Whitman, GJ, Leung, J, Le-Petross, H, Lane, DL, Huo, L, Litton, J, Valero, V, Hunt, KK, Arun, BK, Mohamed, R, Sun, J, Korkut, A, Xu, Z, Pashapoor, S, White, JB, Son, JB, Thompson, A, Wei, P, Ma, J, Moulder, S, Rauch, GM. Early tumor volume reduction by breast DCE MRI predicts pathologic complete response to neoadjuvant therapy in triple negative breast cancer. npj Breast Cancer 11(1), 2025. e-Pub 2025.
2. Rinkenbaugh AL, Qi Y, Cai S, Shao J, Hancock F, Jeter-Jones SL, Zhang X, Powell E, Huo L, Lau R, Fu C, Gould R, Hollander PD, Ravenberg EE, White JB, Rauch GM, Arun B, Yam C, Thompson AM, Echeverria GV, Moulder SL, Symmans W, Chang JT, Piwnica-Worms H. An Annotated Biobank of Triple-Negative Breast Cancer Patient-Derived Xenografts Features Treatment-Naïve and Longitudinal Samples During Neoadjuvant Chemotherapy. Cancer Res 85(21):4062-4080, 2025. PMID: 40801311.
3. Anderson, SA, Bartow, BB, Siegal, GP, Harada, S, Yalniz, C, Khoury, K, Huo, L, Ding, Q, Sahin, AA, Wei, S, Huang, X. Predictive biomarkers for immune checkpoint inhibitor (ICI) and poly (ADP-ribose) polymerase (PARP) inhibitor (PARPi) in advanced-stage breast carcinoma. Human Pathology Reports 40, 2025. e-Pub 2025.
4. Ye, Q, Law, T, Klippel, D, Albarracin, C, Chen, H, Contreras, A, Ding, Q, Huo, L, Khazai, L, Middleton, LP, Resetkova, E, Sahin, AA, Sun, H, Sweeney, K, Symmans, WF, Wu, Y, Yoon, EC, Krishnamurthy, S. Prospective and Retrospective Analysis of Whole-Slide Images of Sentinel and Targeted Lymph Node Frozen Sections in Breast Cancer. Modern Pathology 38(4), 2025. e-Pub 2025. PMID: 39788205.
5. Xu, Z, Zhou, Z, Son, JB, Feng, H, Adrada, BE, Moseley, T, Candelaria, RP, Guirguis, MS, Patel, MM, Whitman, GJ, Leung, J, Le-Petross, H, Mohamed, R, Panthi, B, Lane, DL, Chen, H, Wei, P, Tripathy, D, Litton, J, Valero, V, Huo, L, Hunt, KK, Korkut, A, Thompson, A, Yang, W, Yam, C, Rauch, GM, Ma, J. Deep Learning Models Based on Pretreatment MRI and Clinicopathological Data to Predict Responses to Neoadjuvant Systemic Therapy in Triple-Negative Breast Cancer. Cancers 17(6), 2025. e-Pub 2025. PMID: 40149299.
6. Lee, J, Kida, K, Koh, J, Liu, H, Manyam, GC, Gi, YJ, Rampa, DR, Multani, AS, Wang, J, Jayachandran, G, Lee, DW, Reuben, JM, Sahin, A, Huo, L, Tripathy, D, Im, SA, Ueno, NT. The DNA repair pathway as a therapeutic target to synergize with trastuzumab deruxtecan in HER2-targeted antibody–drug conjugate–resistant HER2-overexpressing breast cancer. Journal of Experimental and Clinical Cancer Research 43(1), 2024. e-Pub 2024. PMID: 39164784.
7. Ye Q, Chen H, Han C, Peng Y, Huang X, Sun H, Wu Y, Albarracin CT, Middleton LP, Sahin AA, Huo L, Ding Q. Nuclear staining for pan-Trk by immunohistochemistry is highly specific for secretory carcinoma of breast: pan-Trk in various subtypes of breast carcinoma. J Clin Pathol 77(11):751-755, 2024. e-Pub 2023. PMID: 37586834.
8. Wanis KN, Goetz L, So A, Glencer AC, Sun SX, Teshome M, Resetkova E, Hwang RF, Hunt KK, Candelaria RP, Huo L, Singh P. The Prevalence of Sentinel Lymph Node Positivity and Implications for the Utility of Frozen Section Diagnosis Following Neoadjuvant Systemic Therapy in Patients with Clinically Node-Negative HER2-Positive or Triple-Negative Breast Cancer. Ann Surg Oncol 31(11):7339-7346, 2024. e-Pub 2024. PMID: 39048903.
9. Musall BC, Rauch DE, Mohamed RMM, Panthi B, Boge M, Candelaria RP, Chen H, Guirguis MS, Hunt KK, Huo L, Hwang KP, Korkut A, Litton JK, Moseley TW, Pashapoor S, Patel MM, Reed BJ, Scoggins ME, Son JB, Tripathy D, Valero V, Wei P, White JB, Whitman GJ, Xu Z, Yang WT, Yam C, Adrada BE, Ma J. Diffusion Tensor Imaging for Characterizing Changes in Triple-Negative Breast Cancer During Neoadjuvant Systemic Therapy. J Magn Reson Imaging 60(4):1367-1376, 2024. e-Pub 2024. PMID: 38294179.
10. Yam, C, Patel, MM, Hill, H, Sun, R, Bassett Jr, R, Kong, EK, Damodaran, S, Koenig, KB, Abouharb, S, Saleem, S, Bisen, AK, Murthy, RK, Ramirez, DL, Rauch, GM, Adrada, BE, Candelaria, RP, Wang, X, Mittendorf, EA, Thompson, A, White, JB, Ravenberg, EE, Clayborn, A, Ding, Q, Booser, DJ, Oke, OC, Brewster, A, Hortobagyi, GN, Ibrahim, NK, Litton, J, Valero, V, Arun, BK, Tripathy, D, Chang, J, Chen, K, Korkut, A, Moulder, S, Huo, L, Lim, B, Ueno, NT. Targeting the Epidermal Growth Factor Receptor Pathway in Chemotherapy-Resistant Triple-Negative Breast Cancer. Cancer Research Communications 4(10):2823-2834, 2024. e-Pub 2024. PMID: 39356138.
11. Mohamed RM, Panthi B, Adrada BE, Boge M, Candelaria RP, Chen H, Guirguis MS, Hunt KK, Huo L, Hwang KP, Korkut A, Litton JK, Moseley TW, Pashapoor S, Patel MM, Reed B, Scoggins ME, Son JB, Thompson A, Tripathy D, Valero V, Wei P, White J, Whitman GJ, Xu Z, Yang W, Yam C, Ma J, Rauch GM. Multiparametric MRI-based radiomic models for early prediction of response to neoadjuvant systemic therapy in triple-negative breast cancer. Sci Rep 14(1):16073, 2024. e-Pub 2024. PMID: 38992094.
12. Lim B, Seth S, Yam C, Huo L, Fujii T, Lee J, Bassett R, Nasser S, Ravenberg L, White J, Clayborn A, Guerra G, Litton JK, Damodaran S, Layman R, Valero V, Tripathy D, Lewis M, Dobrolecki LE, Lei J, Candelaria R, Arun B, Rauch G, Zhao L, Zhang J, Ding Q, Symmans WF, Chang JT, Thompson AM, Moulder SL, Ueno NT. Phase 2 study of neoadjuvant enzalutamide and paclitaxel for luminal androgen receptor-enriched TNBC: Trial results and insights into "ARness". Cell Rep Med 5(6):101595, 2024. e-Pub 2024. PMID: 38838676.
13. Huang X, Anderson SA, Siegal GP, Wei S, Liu S, Yang J, Roisin P, Pickens JT, Huo L, Sahin AA, Granada CP, Chen S. Comparison of PD-L1 (22C3) Expression in Paired Primary and Metastatic Breast Carcinoma. Clin Breast Cancer 24(4):e310-318, 2024. e-Pub 2024. PMID: 38492995.
14. Basho RK, Zhao L, White JB, Huo L, Bassett RL, Mittendorf EA, Thompson A, Litton JK, Ueno N, Arun B, Lim B, Valero V, Tripathy D, Zhang J, Adrada BE, Santiago L, Ravenberg E, Seth S, Yam C, Moulder SL, Damodaran S. Comprehensive Analysis Identifies Variability in PI3K Pathway Alterations in Triple-Negative Breast Cancer Subtypes. JCO Precis Oncol 8:e2300124, 2024. e-Pub 2024. PMID: 38484209.
15. Li X, Lee JH, Gao Y, Zhang J, Bates KM, Rimm DL, Zhang H, Smith GH, Lawson D, Meisel J, Chang J, Huo L. Correlation of HER2 Protein Level With mRNA Level Quantified by RNAscope in Breast Cancer. Mod Pathol 37(2):100408, 2024. e-Pub 2023. PMID: 38135153.
16. Wang J, Peng Y, Sun H, Aung PP, Resetkova E, Yam C, Sahin AA, Huo L, Ding Q. TRPS1 and GATA3 Expression in Invasive Breast Carcinoma With Apocrine Differentiation. Arch Pathol Lab Med 148(2):200-205, 2024. e-Pub 2024. PMID: 37074839.
17. Wang J, Chen H, Koenig J, Wu Y, Bedrosian I, Arun B, Ding Q, Khazai L, Resetkova E, Huo L, Sneige N, Albarracin C. Discordance of Oncotype DX scores in synchronous bilateral and unilateral multifocal breast cancers. Breast Cancer Res Treat 203(1):73-83, 2024. e-Pub 2023. PMID: 37751078.
18. Xu Z, Rauch DE, Mohamed RM, Pashapoor S, Zhou Z, Panthi B, Son JB, Hwang KP, Musall BC, Adrada BE, Candelaria RP, Leung JWT, Le-Petross HTC, Lane DL, Perez F, White J, Clayborn A, Reed B, Chen H, Sun J, Wei P, Thompson A, Korkut A, Huo L, Hunt KK, Litton JK, Valero V, Tripathy D, Yang W, Yam C, Ma J. Deep Learning for Fully Automatic Tumor Segmentation on Serially Acquired Dynamic Contrast-Enhanced MRI Images of Triple-Negative Breast Cancer. Cancers (Basel) 15(19), 2023. e-Pub 2023. PMID: 37835523.
19. Zhang J, Dai H, Huo L, Burks JK, McGrail DJ, Lin SY. Cytosolic DNA accumulation promotes breast cancer immunogenicity via a STING-independent pathway. J Immunother Cancer 11(10), 2023. e-Pub 2023. PMID: 37907220.
20. Abuhadra N, Sun R, Yam C, Rauch GM, Ding Q, Lim B, Thompson AM, Mittendorf EA, Adrada BE, Damodaran S, Virani K, White J, Ravenberg E, Sun J, Choi J, Candelaria R, Arun B, Ueno NT, Santiago L, Saleem S, Abouharb S, Murthy RK, Ibrahim N, Sahin A, Valero V, Symmans WF, Litton JK, Tripathy D, Moulder S, Huo L. Predictive Roles of Baseline Stromal Tumor-Infiltrating Lymphocytes and Ki-67 in Pathologic Complete Response in an Early-Stage Triple-Negative Breast Cancer Prospective Trial. Cancers (Basel) 15(13), 2023. e-Pub 2023. PMID: 37444385.
21. Hwang KP, Elshafeey NA, Kotrotsou A, Chen H, Son JB, Boge M, Mohamed RM, Abdelhafez AH, Adrada BE, Panthi B, Sun J, Musall BC, Zhang S, Candelaria RP, White JB, Ravenberg EE, Tripathy D, Yam C, Litton JK, Huo L, Thompson AM, Wei P, Yang WT, Pagel MD, Ma J, Rauch GM. A Radiomics Model Based on Synthetic MRI Acquisition for Predicting Neoadjuvant Systemic Treatment Response in Triple-Negative Breast Cancer. Radiol Imaging Cancer 5(4):e230009, 2023. e-Pub 2023. PMID: 37505106.
22. Abuhadra N, Sun R, Bassett RL, Huo L, Chang JT, Teshome M, Clayborn AR, White JB, Ravenberg EE, Adrada BE, Candelaria RP, Yang W, Ding Q, Symmans WF, Arun B, Damodaran S, Koenig KB, Layman RM, Lim B, Litton JK, Thompson A, Ueno NT, Piwnica-Worms H, Hortobagyi GN, Valero V, Tripathy D, Rauch GM, Moulder S, Yam C. Targeting chemotherapy resistance in mesenchymal triple-negative breast cancer: a phase II trial of neoadjuvant angiogenic and mTOR inhibition with chemotherapy. Invest New Drugs 41(3):391-401, 2023. e-Pub 2023. PMID: 37043123.
23. Yam C, Mittendorf EA, Garber HR, Sun R, Damodaran S, Murthy RK, Ramirez D, Karuturi M, Layman RM, Ibrahim N, Rauch GM, Adrada BE, Candelaria RP, White JB, Ravenberg E, Clayborn A, Ding QQ, Symmans WF, Prabhakaran S, Thompson AM, Valero V, Tripathy D, Huo L, Moulder SL, Litton JK. A phase II study of neoadjuvant atezolizumab and nab-paclitaxel in patients with anthracycline-resistant early-stage triple-negative breast cancer. Breast Cancer Res Treat 199(3):457-469, 2023. e-Pub 2023. PMID: 37061619.
24. Wang M, Ding Q, Gu J, Sfamenos SM, Huo L, Tang Z, Sun H, Robinson M, Tang G, Lim B, Wu Y, Albarracin CT, Sahin AA, Chen H. Breast Cancer With a HER2 FISH Group 2 Result: Should HER2 Tests be Repeated?. Clin Breast Cancer 23(4):415-422, 2023. e-Pub 2023. PMID: 36878823.
25. Bartow BB, Siegal GP, Yalniz C, Elkhanany AM, Huo L, Ding Q, Sahin AA, Guo H, Magi-Galluzzi C, Harada S, Huang X. Mutations in Homologous Recombination Genes and Loss of Heterozygosity Status in Advanced-Stage Breast Carcinoma. Cancers (Basel) 15(9), 2023. e-Pub 2023. PMID: 37173992.
26. Zhang X, Yao J, Niu N, Li X, Liu Y, Huo L, Euscher ED, Wang H, Bell D, Sood AK, Wang G, Lawson BC, Ramalingam P, Malpica A, Sahin AA, Ding Q, Liu J. SOX17: A Highly Sensitive and Specific Immunomarker for Ovarian and Endometrial Carcinomas. Mod Pathol 36(2):100001, 2023. e-Pub 2023. PMID: 36853778.
27. Panthi B, Adrada BE, Candelaria RP, Guirguis MS, Yam C, Boge M, Chen H, Hunt KK, Huo L, Hwang KP, Korkut A, Lane DL, Le-Petross HC, Leung JWT, Litton JK, Mohamed RM, Musall BC, Pashapoor S, Patel MM, Perez F, Son JB, Thompson A, Valero V, Wei P, White J, Xu Z, Pinsky L, Tripathy D, Yang W, Ma J, Rauch GM. Assessment of Response to Neoadjuvant Systemic Treatment in Triple-Negative Breast Cancer Using Functional Tumor Volumes from Longitudinal Dynamic Contrast-Enhanced MRI. Cancers (Basel) 15(4), 2023. e-Pub 2023. PMID: 36831368.
28. Panthi B, Mohamed RM, Adrada BE, Boge M, Candelaria RP, Chen H, Hunt KK, Huo L, Hwang KP, Korkut A, Lane DL, Le-Petross HC, Leung JWT, Litton JK, Pashapoor S, Perez F, Son JB, Sun J, Thompson A, Tripathy D, Valero V, Wei P, White J, Xu Z, Yang W, Zhou Z, Yam C, Rauch GM, Ma J. Longitudinal dynamic contrast-enhanced MRI radiomic models for early prediction of response to neoadjuvant systemic therapy in triple-negative breast cancer. Front Oncol 13, 2023. e-Pub 2023. PMID: 37941561.
29. Chen H, Ding Q, Khazai L, Zhao L, Damodaran S, Litton JK, Rauch GM, Yam C, Chang JT, Seth S, Lim B, Thompson AM, Mittendorf EA, Adrada B, Virani K, White JB, Ravenberg E, Song X, Candelaria R, Arun B, Ueno NT, Santiago L, Saleem S, Abouharb S, Murthy RK, Ibrahim N, Routbort MJ, Sahin A, Valero V, Symmans WF, Tripathy D, Wang WL, Moulder S, Huo L. PTEN in triple-negative breast carcinoma: protein expression and genomic alteration in pretreatment and posttreatment specimens. Ther Adv Med Oncol 15, 2023. e-Pub 2023. PMID: 37547448.
30. Echeverria GV, Cai S, Tu Y, Shao J, Powell E, Redwood AB, Jiang Y, McCoy A, Rinkenbaugh AL, Lau R, Trevarton AJ, Fu C, Gould R, Ravenberg EE, Huo L, Candelaria R, Santiago L, Adrada BE, Lane DL, Rauch GM, Yang WT, White JB, Chang JT, Moulder SL, Symmans WF, Hilsenbeck SG, Piwnica-Worms H. Predictors of success in establishing orthotopic patient-derived xenograft models of triple negative breast cancer. NPJ Breast Cancer 9(1):2, 2023. e-Pub 2023. PMID: 36627285.
31. Lee, JJ, Kida, K, Liu, H, Gi, YJ, Manyam, GC, Wang, J, Multani, AS, Huo, L, Tripathy, D, Ueno, NT. The DNA repair pathway as a therapeutic target to synergize with trastuzumab deruxtecan, an anti-HER2 antibody-drug conjugate. 34th EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics, 2022.
32. Wu C, Jarrett AM, Zhou Z, Elshafeey N, Adrada BE, Candelaria RP, Mohamed RMM, Boge M, Huo L, White JB, Tripathy D, Valero V, Litton JK, Yam C, Son JB, Ma J, Rauch GM, Yankeelov TE. MRI-based digital models forecast patient-specific treatment responses to neoadjuvant chemotherapy in triple-negative breast cancer. Cancer Res 82(18):3394-3404, 2022. e-Pub 2022. PMID: 35914239.
33. Shen T, Zhao J, Zhao M, Taggart MW, Ramalingam P, Gong Y, Wu Y, Liu H, Zhang J, Resetkova E, Wang WL, Ding Q, Huo L, Yoon E. Unusual Staining of Immunohistochemical Markers PAX8 and CDX2 in Breast Carcinoma: A Potential Diagnostic Pitfall. Hum Pathol 125:35-47, 2022. e-Pub 2022. PMID: 35417734.
34. Yam C, Abuhadra N, Sun R, Adrada BE, Ding QQ, White JB, Ravenberg EE, Clayborn AR, Valero V, Tripathy D, Damodaran S, Arun BK, Litton JK, Ueno NT, Murthy RK, Lim B, Baez L, Li X, Buzdar AU, Hortobagyi GN, Thompson AM, Mittendorf EA, Rauch GM, Candelaria RP, Huo L, Moulder SL, Chang JT. Molecular Characterization and Prospective Evaluation of Pathologic Response and Outcomes with Neoadjuvant Therapy in Metaplastic Triple-Negative Breast Cancer. Clin Cancer Res 28(13):2878-2889, 2022. e-Pub 2022. PMID: 35507014.
35. Zhou P, Chang N, Abraham SC, Albarracin CT, Huo L, Chen H, Ding Q, Resetkova E, Middleton LP, Sahin AA, Bu H, Wu Y. Metastatic non-Hematopoietic Neoplasms to the Breast: A Study of 238 Cases. Hum Pathol 125:59-67, 2022. e-Pub 2022. PMID: 35447141.
36. Yoon EC, Wang G, Parkinson B, Huo L, Peng Y, Wang J, Salisbury T, Wu Y, Chen H, Albarracin CT, Resetkova E, Middleton LP, Krishnamurthy S, Gan Q, Sun H, Huang X, Shen T, Chen W, Parwani AV, Sahin AA, Li Z, Ding Q. TRPS1, GATA3, and SOX10 expression in triple-negative breast carcinoma. Hum Pathol 125:97-107, 2022. e-Pub 2022. PMID: 35413381.
37. Jimenez JE, Abdelhafez A, Mittendorf EA, Elshafeey N, Yung JP, Litton JK, Adrada BE, Candelaria RP, White J, Thompson AM, Huo L, Wei P, Tripathy D, Valero V, Yam C, Hazle JD, Moulder SL, Yang WT, Rauch GM. A model combining pretreatment MRI radiomic features and tumor-infiltrating lymphocytes to predict response to neoadjuvant systemic therapy in triple-negative breast cancer. Eur J Radiol 149:110220, 2022. e-Pub 2022. PMID: 35193025.
38. Villodre ES, Hu X, Eckhardt BL, Larson R, Huo L, Yoon EC, Gong Y, Song J, Liu S, Ueno NT, Krishnamurthy S, Pusch S, Tripathy D, Woodward WA, Debeb BG. NDRG1 in Aggressive Breast Cancer Progression and Brain Metastasis. J Natl Cancer Inst 114(4):579-591, 2022. e-Pub 2022. PMID: 34893874.
39. Wang J, Wang WL, Sun H, Huo L, Wu Y, Chen H, Gan Q, Meis JM, Maloney N, Lazar AJ, Yoon EC, Albarracin CT, Krishnamurthy S, Middleton LP, Resetkova E, Yu W, Tan D, Lu W, Solis Soto LM, Wang S, Wistuba II, Parwani AV, Prieto VG, Sahin AA, Li Z, Ding Q. Expression of TRPS1 in phyllodes tumor and sarcoma of the breast. Hum Pathol 121:73-80, 2022. e-Pub 2022. PMID: 35063444.
40. Abuhadra N, Sun R, Litton JK, Rauch GM, Yam C, Chang JT, Seth S, Bassett R, Lim B, Thompson AM, Mittendorf E, Adrada BE, Damodaran S, White J, Ravenberg E, Candelaria R, Arun B, Ueno NT, Santiago L, Saleem S, Abouharb S, Murthy RK, Ibrahim N, Sahin AA, Valero V, Symmans WF, Tripathy D, Moulder S, Huo L. Prognostic Impact of High Baseline Stromal Tumor-Infiltrating Lymphocytes in the Absence of Pathologic Complete Response in Early-Stage Triple-Negative Breast Cancer. Cancers (Basel) 14(5):1323, 2022. e-Pub 2022. PMID: 35267631.
41. Candelaria RP, Spak DA, Rauch GM, Huo L, Bassett RL, Santiago L, Scoggins ME, Guirguis MS, Patel MM, Whitman GJ, Moulder SL, Thompson AM, Ravenberg EE, White JB, Abuhadra NK, Valero V, Litton J, Adrada BE, Yang WT. BI-RADS Ultrasound Lexicon Descriptors and Stromal Tumor-Infiltrating Lymphocytes in Triple-Negative Breast Cancer. Acad Radiol 29 Suppl 1:S35-S41, 2022. e-Pub 2021. PMID: 34272161.
42. Yam C, Yen EY, Chang JT, Bassett RL, Alatrash G, Garber H, Huo L, Yang F, Philips AV, Ding QQ, Lim B, Ueno NT, Kannan K, Sun X, Sun B, Parra Cuentas ER, Symmans WF, White JB, Ravenberg E, Seth S, Guerriero JL, Rauch GM, Damodaran S, Litton JK, Wargo JA, Hortobagyi GN, Futreal A, Wistuba II, Sun R, Moulder SL, Mittendorf EA. Immune Phenotype and Response to Neoadjuvant Therapy in Triple-Negative Breast Cancer. Clin Cancer Res 27(19):5365-5375, 2021. e-Pub 2021. PMID: 34253579.
43. Shah VV, Duncan AD, Jiang S, Stratton SA, Allton KL, Yam C, Jain A, Krause PM, Lu Y, Cai S, Tu Y, Zhou X, Zhang X, Jiang Y, Carroll CL, Kang Z, Liu B, Shen J, Gagea M, Manu SM, Huo L, Gilcrease M, Powell RT, Guo L, Stephan C, Davies PJ, Parker-Thornburg J, Lozano G, Behringer RR, Piwnica-Worms H, Chang JT, Moulder SL, Barton MC. Mammary-specific expression of Trim24 establishes a mouse model of human metaplastic breast cancer. Nat Commun 12(1):5389, 2021. e-Pub 2021. PMID: 34508101.
44. Ai D, Yao J, Yang F, Huo L, Chen H, Lu W, Soto LMS, Jiang M, Raso MG, Wang S, Bell D, Liu J, Wang H, Tan D, Torres-Cabala C, Gan Q, Wu Y, Albarracin C, Hung MC, Meric-Bernstam F, Wistuba II, Prieto VG, Sahin AA, Ding Q. TRPS1: a highly sensitive and specific marker for breast carcinoma, especially for triple-negative breast cancer. Mod Pathol 34(4):710-719, 2021. e-Pub 2020. PMID: 33011748.
45. Yam C, Rauch GM, Rahman T, Karuturi M, Ravenberg E, White J, Clayborn A, McCarthy P, Abouharb S, Lim B, Litton JK, Ramirez DL, Saleem S, Stec J, Symmans WF, Huo L, Damodaran S, Sun R, Moulder SL. A phase II study of Mirvetuximab Soravtansine in triple-negative breast cancer. Invest New Drugs 39(2):509-515, 2021. e-Pub 2020. PMID: 32984932.
46. Yang L, Roy M, Lin H, Shen Y, Albarracin C, Huo L, Chen H, Wei B, Bedrosian I, Bu H, Wu Y. Validation of prognostic significance of the proposed uniform classification framework in neuroendocrine neoplasms of the breast. Breast Cancer Res Treat 186(2):403-415, 2021. e-Pub 2021. PMID: 33528758.
47. Huang X, Ding Q, Guo H, Gong Y, Zhao J, Zhao M, Sui D, Wu Y, Chen H, Liu H, Zhang J, Resetkova E, Moulder SL, Wang WL, Huo L. Comparison of three FDA-approved diagnostic immunohistochemistry assays of PD-L1 in triple-negative breast carcinoma. Hum Pathol 108:42-50, 2021. e-Pub 2020. PMID: 33221342.
48. Villodre ES, Gong Y, Hu X, Huo L, Yoon EC, Ueno NT, Woodward WA, Tripathy D, Song J, Debeb BG. NDRG1 Expression Is an Independent Prognostic Factor in Inflammatory Breast Cancer. Cancers (Basel) 12(12):3711, 2020. e-Pub 2020. PMID: 33321961.
49. Chang G, Shi L, Ye Y, Shi H, Zeng L, Tiwary S, Huse JT, Huo L, Ma L, Ma Y, Zhang S, Zhu J, Xie V, Li P, Han L, He C, Huang S. YTHDF3 Induces the Translation of m6A-Enriched Gene Transcripts to Promote Breast Cancer Brain Metastasis. Cancer Cell:857-871, 2020. e-Pub 2020. PMID: 33125861.
50. Yalniz C, Meis JM, Wang WL, Huo L, Candelaria RP, Adrada BE, Lane D, Santiago L, Huang ML. Proliferative fasciitis mimicking sarcoma in the breast. Breast J. e-Pub 2020. PMID: 32854140.
51. Guo H, Ding Q, Gong Y, Gilcrease MZ, Zhao M, Zhao J, Sui D, Wu Y, Chen H, Liu H, Zhang J, Resetkova E, Moulder SL, Wang WL, Huo L. Comparison of three scoring methods using the FDA-approved 22C3 immunohistochemistry assay to evaluate PD-L1 expression in breast cancer and their association with clinicopathologic factors. Breast Cancer Res 22(1):69, 2020. e-Pub 2020. PMID: 32576238.
52. Shannon VR, Subudhi SK, Huo L, Faiz SA. Diffuse alveolar hemorrhage with nivolumab monotherapy. Respir Med Case Rep 30:101131, 2020. e-Pub 2020. PMID: 32577370.
53. Moseley TW, Shah SS, Nguyen CV, Rosenblat J, Resetkova E, Sneige N, Brandt KR, Huo L. Clinical Management of Mucocele-Like Lesions of the Breast with Limited or no Epithelial Atypia on Core Biopsy: Experience from Two Institutions. Ann Surg Oncol 26(11):3478-3488, 2019. e-Pub 2019. PMID: 31187364.
54. Candelaria RP, Adrada BE, Wei W, Thompson AM, Santiago L, Lane DL, Huang ML, Arribas EM, Rauch GM, Symmans WF, Gilcrease MZ, Huo L, Lim B, Ueno NT, Moulder SL, Yang WT. Imaging features of triple-negative breast cancers according to androgen receptor status. Eur J Radiol 114:167-174, 2019. e-Pub 2019. PMID: 31005169.
55. Ding Q, Wang Y, Zuo Z, Gong Y, Krishnamurthy S, Li CW, Lai YJ, Wei W, Wang J, Manyam GC, Diao L, Zhang X, Lin F, Symmans WF, Sun L, Liu CG, Liu X, Debeb BG, Ueno NT, Harano K, Alvarez RH, Wu Y, Cristofanilli M, Huo L. Decreased expression of microRNA-26b in locally advanced and inflammatory breast cancer. Hum Pathol 7(77):121-129, 2018. e-Pub 2018. PMID: 29689244.
56. He J, Huo L, Ma J, Zhao J, Bassett RL, Sun X, Ueno NT, Lim B, Gong Y. Expression of Programmed Death Ligand 1 (PD-L1) in Posttreatment Primary Inflammatory Breast Cancers and Clinical Implications. Am J Clin Pathol 149(3):253-261, 2018. e-Pub 2018. PMID: 29425258.
57. Fujii T, Reuben JM, Huo L, Espinosa Fernandez JR, Gong Y, Krupa R, Suraneni MV, Graf RP, Lee J, Greene S, Rodriguez A, Dugan L, Louw J, Lim B, Barcenas CH, Marx AN, Tripathy D, Wang Y, Landers M, Dittamore R, Ueno NT. Androgen receptor expression on circulating tumor cells in metastatic breast cancer. PLoS One 12(9):e0185231, 2017. e-Pub 2017. PMID: 28957377.
58. Wu H, Bi J, Peng Y, Huo L, Yu X, Yang Z, Zhou Y, Qin L, Xu Y, Liao L, Xie Y, Conneely OM, Jonkers J, Xu J. Nuclear receptor NR4A1 is a tumor suppressor down-regulated in triple-negative breast cancer. Oncotarget 8(33):54364-54377, 2017. e-Pub 2017. PMID: 28903348.
59. Li X, Yang J, Krishnamurti U, Huo L, Ward KC, O'Regan R, Peng L. Hormone receptor-positive breast cancer has a worse prognosis in male than in female patients. Clin Breast Cancer 17(5):356-366, 2017. e-Pub 2017. PMID: 28576631.
60. Chen H, Singh RR, Lu X, Huo L, Yao H, Aldape K, Abraham R, Virani S, Mehrotra M, Mishra BM, Bousamra A, Albarracin C, Wu Y, Roy-Chowdhuri S, Shamanna RK, Routbort MJ, Medeiros LJ, Patel KP, Broaddus R, Sahin A, Luthra R. Genome-wide copy number aberrations and HER2 and FGFR1 alterations in primary breast cancer by molecular inversion probe microarray. Oncotarget 8(7):10845-10857, 2017. e-Pub 2017. PMID: 28125801.
61. Li X, Yang J, Peng L, Sahin AA, Huo L, Ward KC, O'Regan R, Torres MA, Meisel JL. Triple-negative breast cancer has worse overall survival and cause-specific survival than non-triple-negative breast cancer. Breast Cancer Res Treat 161(2):279-287, 2017. e-Pub 2016. PMID: 27888421.
62. Kono M, Fujii T, Lyons GR, Huo L, Bassett R, Gong Y, Karuturi MS, Tripathy D, Ueno NT. Impact of androgen receptor expression in fluoxymesterone-treated estrogen receptor-positive metastatic breast cancer refractory to contemporary hormonal therapy. Breast Cancer Res Treat 160(1):101-109, 2016. e-Pub 2016. PMID: 27663436.
63. Vila J, Mittendorf EA, Basset RL, Bedrosian I, Shaitelman SF, Stauder MC, Chavez-McGregor M, Litton JF, Yang WT, Huo L, Kuerer HM, Hunt KK, Caudle AS. Nomograms to predict axillary response to neoadjuvant chemotherapy in clinically node positive breast cancer patients. Ann Surg Oncol 23(11):3501-3509, 2016. e-Pub 2016. PMID: 27216742.
64. He H, Plaxco JS, Wei W, Huo L, Candelaria RP, Kuerer HM, Yang WT. Incremental cancer detection using breast ultrasonography versus breast magnetic resonance imaging in the evaluation of newly diagnosed breast cancer patients. Br J Radiol 89(1065):1065, 2016. e-Pub 2016. PMID: 27384241.
65. Debeb BG, Lacerda L, Anfossi S, Diagaradjane P, Chu K, Bambhroliya A, Huo L, Wei C, Larson RA, Wolfe AR, Xu W, Smith DL, Li L, Ivan C, Allen PK, Wu W, Calin GA, Krishnamurthy S, Zhang XH, Buchholz TA, Ueno NT, Reuben JM, Woodward WA. miR-141-Mediated regulation of brain metastasis from breast cancer. J Natl Cancer Inst 108(8), 2016. e-Pub 2016. PMID: 27075851.
66. Wolfe AR, Bambhroliya A, Reddy JP, Debeb BG, Huo L, Larson R, Li L, Ueno NT, Woodward WA. MiR-33a Decreases high-density lipoprotein-induced radiation sensitivity in breast cancer. Int J Radiat Oncol Biol Phys 95(2):791-9, 2016. e-Pub 2016. PMID: 27055396.
67. Huo L, Wang Y, Gong Y, Krishnamurthy S, Wang J, Diao L, Liu CG, Liu X, Lin F, Symmans WF, Wei W, Zhang X, Sun L, Alvarez RH, Ueno NT, Fouad TM, Harano K, Debeb BG, Wu Y, Reuben J, Cristofanilli M, Zuo Z. MicroRNA expression profiling identifies decreased expression of miR-205 in inflammatory breast cancer. Mod Pathol 29(4):330-46, 2016. e-Pub 2016. PMID: 26916073.
68. Liao Q, Liu W, Liu Y, Wang F, Wang C, Zhang J, Chu M, Jiang D, Xiao L, Shao W, Sheng Z, Tao X, Huo L, Yin CC, Zhang Y, Lee G, Huang J, Li Z, Qiu X. Aberrant high expression of immunoglobulin G in epithelial stem/progenitor-like cells contributes to tumor initiation and metastasis. Oncotarget 24(6):40081-94, 2015. e-Pub 2015. PMID: 26472025.
69. Huo L, Gong Y, Guo M, Gilcrease MZ, Wu Y, Zhang H, Zhang J, Resetkova E, Hunt KK, Deavers MT. GATA-binding protein 3 enhances the utility of gross cystic disease fluid protein-15 and mammaglobin A in triple-negative breast cancer by immunohistochemistry. Histopathology 67(2):245-54, 2015. e-Pub 2015. PMID: 25564996.
70. Guo M, Khanna A, Feng J, Patel S, Zhang W, Gong Y, Huo L, Staerkel G. Analytical Performance of Cervista HPV 16/18 in SurePath Pap Specimens. Diagn Cytopathol 43(4):301-6, 2015. e-Pub 2014. PMID: 25352375.
71. Adrada BE, Huo L, Lane DL, Arribas EM, Resetkova E, Yang W. Histopathologic correlation of residual mammographic microcalcifications after neoadjuvant chemotherapy for locally advanced breast cancer. Ann Surg Oncol 22(4):1111-7, 2015. e-Pub 2014. PMID: 25287438.
72. Zhang S, Huo L, Arribas E, Middleton LP. Adenomyoepithelioma of the breast with associated atypical lobular hyperplasia: a previously unrecognized association with management implications. Ann Diagn Pathol 19(1):20-3, 2015. e-Pub 2015. PMID: 25631879.
73. Chen J, Lee HJ, Wu X, Huo L, Kim SJ, Xu L, Wang Y, He J, Reddy Bollu L, Gao G, Su F, Briggs J, Liu X, Melman T, Asara JM, Fidler IJ, Cantley LC, Locasale JW, Weihua Z. Gain of glucose-independent growth upon metastasis of breast cancer cells to the brain. Cancer Research 3(75):554-65, 2015. e-Pub 2015. PMID: 25511375.
74. Rueth NM, Black DM, Limmer AR, Gabriel E, Huo L, Fornage BD, Dogan BE, Chavez-MacGregor M, Yi M, Hunt KK, Strom EA. Breast conservation in the setting of contemporary multimodality treatment provides excellent outcomes for patients with occult primary breast cancer. Ann Surg Oncol 22(1):90-5, 2015. e-Pub 2014. PMID: 25249256.
75. Thaker NG, Hoffman KE, Stauder MC, Shaitelman SF, Strom EA, Tereffe W, Smith BD, Perkins GH, Huo L, Munsell MF, Pusztai L, Buchholz TA, Woodward WA. The 21-gene recurrence score complements IBTR! Estimates in early-stage, hormone receptor-positive, HER2-normal, lymph node-negative breast cancer. Springerplus 4:36, 2015. e-Pub 2015. PMID: 25674496.
76. Xiang DB, Wei B, Abraham SC, Huo L, Albarracin CT, Zhang H, Babiera G, Caudle AS, Akay CL, Rao P, Zhao YJ, Lu X, Wu Y. Molecular cytogenetic characterization of mammary neuroendocrine carcinoma. Hum Pathol 45(9):1951-6, 2014. e-Pub 2014. PMID: 25074542.
77. Debeb BG, Gong Y, Atkinson RL, Sneige N, Huo L, Gonzalez-Angulo A, Hung MC, Valero V, Ueno NT, Woodward WA. EZH2 expression correlates with locoregional recurrence after radiation in inflammatory breast cancer. J Exp Clin Cancer Res 33(1), 2014. e-Pub 2014. PMID: 25051981.
78. Gong Y, Wei W, Wu Y, Ueno NT, Huo L. Expression of androgen receptor in inflammatory breast cancer and its clinical relevance. Cancer 120(12):1775-9, 2014. e-Pub 2014. PMID: 24634055.
79. Gong Y, Wang J, Huo L, Wei W, Ueno NT, Woodward WA. Aldehyde dehydrogenase 1 expression in inflammatory breast cancer as measured by immunohistochemical staining. Clin Breast Cancer 14(3):e81-8, 2014. e-Pub 2013. PMID: 24461456.
80. Yi M, Huo L, Koenig KB, Mittendorf EA, Meric-Bernstam F, Kuerer HM, Bedrosian I, Buzdar AU, Symmans WF, Crow JR, Bender M, Shah RR, Hortobagyi GN, Hunt KK. Which threshold for ER positivity? a retrospective study based on 9639 patients. Ann Oncol 25(5):1004-1011, 2014. e-Pub 2014. PMID: 24562447.
81. Akay CL, Ueno NT, Chisholm GB, Hortobagyi GN, Woodward WA, Alvarez RH, Bedrosian I, Kuerer HM, Hunt KK, Huo L, Babiera GV. Primary tumor resection as a component of multimodality treatment may improve local control and survival in patients with stage IV inflammatory breast cancer. Cancer 120(9):1319-28, 2014. e-Pub 2014. PMID: 24510381.
82. Nayak A, Carkaci S, Gilcrease MZ, Liu P, Middleton LP, Bassett RL, Zhang J, Zhang H, Coyne RL, Bevers TB, Sneige N, Huo L. Benign papillomas without atypia diagnosed on core needle biopsy: experience from a single institution and proposed criteria for excision. Clin Breast Cancer 13(6):439-49, 2013. e-Pub 2013. PMID: 24119786.
83. Zhao L, Gong Y, Wang J, Dawlett M, Huo L, Caraway NP, Guo M. Ultrasound-guided fine-needle aspiration biopsy of thyroid bed lesions from patients with thyroidectomy for thyroid carcinomas. Cancer Cytopathol 121(2):101-7, 2013. e-Pub 2012. PMID: 22605565.
84. Li X, Deavers MT, Guo M, Liu P, Gong Y, Albarracin CT, Middleton LP, Huo L. The effect of prolonged cold ischemia time on estrogen receptor immunohistochemistry in breast cancer. Mod Pathol 26(1):71-8, 2013. e-Pub 2012. PMID: 22899286.
85. Huo L, Zhang J, Gilcrease MZ, Gong Y, Wu Y, Zhang H, Resetkova E, Hunt KK, Deavers MT. Gross cystic disease fluid protein-15 and mammaglobin A expression determined by immunohistochemistry is of limited utility in triple-negative breast cancer. Histopathology 62(2):267-74, 2013. e-Pub 2012. PMID: 22963676.
86. Krishnamurthy S, Woodward W, Yang W, Reuben JM, Tepperberg J, Ogura D, Niwa S, Huo L, Gong Y, El-Zein R, Gonzalez-Angulo AM, Chavez-Macgregor M, Alvarez R, Lucci A, Valero V, Ueno NT. Status of the anaplastic lymphoma kinase (ALK) gene in inflammatory breast carcinoma. Springerplus 2:409, 2013. e-Pub 2013. PMID: 24156086.
87. Xiao Y, Lu L, Zhang A, Zhang Y, Sun L, Huo L, Li F. Highly enhanced acetone sensing performances of porous and single crystalline ZnO nanosheets: high percentage of exposed (100) facets working together with surface modification with Pd nanoparticles. ACS Appl Mater Interfaces 4(8):3797-804, 2012. e-Pub 2012. PMID: 22853192.
88. Xu J, Wan M, He Q, Bassett RL, Fu X, Chen AC, Shi F, Creighton CJ, Schiff R, Huo L, Liu D. SGK3 is associated with estrogen receptor expression in breast cancer. Breast Cancer Res Treat 134(2):531-41, 2012. e-Pub 2012. PMID: 22576469.
89. Adejolu M, Huo L, Rohren E, Santiago L, Yang WT. False-positive lesions mimicking breast cancer on FDG PET and PET/CT. AJR Am J Roentgenol 198(3):W304-14, 2012. e-Pub 2012. PMID: 22358030.
90. Lester TR, Hunt KK, Nayeemuddin KM, Bassett RL, Gonzalez-Angulo AM, Feig BW, Huo L, Rourke LL, Davis WG, Valero V, Gilcrease MZ. Metaplastic sarcomatoid carcinoma of the breast appears more aggressive than other triple receptor-negative breast cancers. Breast Cancer Res Treat 131(1):41-8, 2012. e-Pub 2011. PMID: 21331622.
91. Blessing A, Xu L, Gao G, Bollu LR, Li H, Wu X, Ren J, Su F, Huang WC, Hung MC, Huo L, Palapattu GS, Weihua Z. Sodium/glucose co-transporter 1 expression increases in human diseased prostate. J Cancer Sci Ther 4(9):306-12, 2012. e-Pub 2012.
92. Gong Y, Huo L, Liu P, Sneige N, Sun X, Ueno NT, Lucci A, Buchholz TA, Valero V, Cristofanilli M. Polycomb group protein EZH2 is frequently expressed in inflammatory breast cancer and is predictive of worse clinical outcome. Cancer 117(24):5476-84, 2011. e-Pub 2011. PMID: 21713757.
93. McLemore MS, Huo L, Deavers MT, Curry JL, Torres-Cabala CA, Wang WL, Prieto VG. Cutaneous epithelioid angiomatous nodule of the chest wall with expression of estrogen receptor: a mimic of carcinoma and a potential diagnostic pitfall. J Cutan Pathol 38(10):818-22, 2011. e-Pub 2011. PMID: 21752053.
94. Tian Z, Wei B, Tang F, Wei W, Gilcrease MZ, Huo L, Albarracin CT, Resetkova E, Middleton L, Sahin A, Xing Y, Hunt KK, Chen J, Bu H, Rashid A, Abraham SC, Wu Y. Prognostic significance of tumor grading and staging in mammary carcinomas with neuroendocrine differentiation. Hum Pathol 42(8):1169-77, 2011. e-Pub 2011. PMID: 21334720.
95. Huo L. A practical approach to grossing breast specimens. Ann Diagn Pathol 15(4):291-301, 2011. e-Pub 2011. PMID: 21745648.
96. Tang F, Wei B, Tian Z, Gilcrease MZ, Huo L, Albarracin CT, Resetkova E, Zhang H, Sahin A, Chen J, Bu H, Abraham S, Wu Y. Invasive mammary carcinoma with neuroendocrine differentiation: histological features and diagnostic challenges. Histopathology 59(1):106-15, 2011. e-Pub 2011. PMID: 21668471.
97. Lee YS, Mathew J, Dogan BE, Resetkova E, Huo L, Yang WT. Imaging features of micropapillary DCIS: correlation with clinical and histopathological findings. Acad Radiol 18(7):797-803, 2011. e-Pub 2011. PMID: 21419669.
98. Huo L, Bell D, Qiu H, Sahin A, Wu Y, Sneige N. Paneth cell-like eosinophilic cytoplasmic granules in breast carcinoma. Ann Diagn Pathol 15(2):84-92, 2011. e-Pub 2010. PMID: 21163678.
99. Brown AS, Hunt KK, Shen J, Huo L, Babiera GV, Ross MI, Meric-Bernstam F, Feig BW, Kuerer HM, Boughey JC, Ching CD, Gilcrease MZ. Histologic changes associated with false-negative sentinel lymph nodes after preoperative chemotherapy in patients with confirmed lymph node-positive breast cancer before treatment. Cancer 116(12):2878-83, 2010. e-Pub 2010. PMID: 20564394.
100. Huo L, Gilcrease MZ. Fibroepithelial lesions of the breast with pleomorphic stromal giant cells: a clinicopathologic study of 4 cases and review of the literature. Ann Diagn Pathol 13(4):226-32, 2009. e-Pub 2009. PMID: 19608080.
101. Nguyen CV, Deavers MT, Quinones J, Huo L. Estrogen receptor immunohistochemistry for confirmation of sentinel lymph node metastasis in cases with equivocal cytokeratin positivity. Appl Immunohistochem Mol Morphol 17(2):139-145, 2009. e-Pub 2009. PMID: 19521277.
102. Huo L, Sneige N, Hunt KK, Albarracin CT, Lopez A, Resetkova E. Predictors of invasion in patients with core-needle biopsy-diagnosed ductal carcinoma in situ and recommendations for a selective approach to sentinel lymph node biopsy in ductal carcinoma in situ. Cancer 107(8):1760-1768, 2006. e-Pub 2006. PMID: 16977650.
103. Huo L, Moran CA, Fuller GN, Gladish G, Suster S. Pulmonary artery sarcoma: a clinicopathologic and immunohistochemical study of 12 cases. Am J Clin Pathol 125(3):419-424, 2006. e-Pub 2006. PMID: 16613346.
104. Huo L, Lai S, Gladish G, Czerniak BA, Moran CA. Pulmonary artery angiosarcoma: a clinicopathologic and radiological correlation. Ann Diagn Pathol 9(4):209-214, 2005. e-Pub 2005. PMID: 16084454.
105. Huo L, Sugimura J, Tretiakova MS, Patton KT, Gupta R, Popov B, Laskin WB, Yeldandi A, Teh BT, Yang XJ. C-kit expression in renal oncocytomas and chromophobe renal cell carcinomas. Hum Pathol 36(3):262-268, 2005. e-Pub 2005. PMID: 15791570.
106. Gong Y, Sun X, Huo L, Wiley EL, Rao MS. Expression of cell adhesion molecules, CD44s and E-cadherin, and microvessel density in invasive micropapillary carcinoma of the breast. Histopathology 46(1):24-30, 2005. e-Pub 2005. PMID: 15656882.
107. Patton KT, Tretiakova MS, Yao JL, Papavero V, Huo L, Adley BP, Wu G, Huang J, Pins MR, Teh BT, Yang XJ. Expression of RON proto-oncogene in renal oncocytoma and chromophobe renal cell carcinoma. Am J Surg Pathol 28(8):1045-50, 2004. e-Pub 2004. PMID: 15252311.
108. Huo L, Scarpulla RC. Mitochondrial DNA instability and peri-implantation lethality associated with targeted disruption of nuclear respiratory factor 1 in mice. Mol Cell Biol 21(2):644-654, 2001. e-Pub 2001. PMID: 11134350.
109. Huo L, Scarpulla RC. Multiple 5'-untranslated exons in the nuclear respiratory factor 1 gene span 47 kb and contribute to transcript heterogeneity and translational efficiency. Gene 233(1-2):213-224, 1999. e-Pub 1999. PMID: 10375638.

Invited Articles

1. Moseley TW, Shah SS, Brandt KR, Huo L. ASO Author Reflections: Mucocele-Like Lesions of the Breast-Excision or No Excision?. Ann Surg Oncol 26(Suppl 3):826-827, 2019. e-Pub 2019. PMID: 31691107.
2. Huo L. Commentary on: Expression of breast cancer stem cell markers as predictors of prognosis and response to trastuzumab in HER2-positive breast cancer. Breast Disease: A Year Book Quarterly 27(4):278-279, 2017. e-Pub 2017.
3. Huo L. Commentary on: Androgen Receptor Expression in breast cancer in relation to molecular phenotype: Results from the Nurses’ Health Study. Breast Diseases: A Year Book Quarterly 23(2):155-156, 2012. e-Pub 2012.
4. Huo L. Commentary on: Phenotypic Alterations in Ductal Carcinoma In Situ-associated Myoepithelial Cells: Biologic and Diagnostic Implications. Breast Diseases: A Year Book Quarterly 20(4):402-404, 2009. e-Pub 2009.
5. Huo L. Commentary on: HER2 Testing by Local, Central, and Reference Laboratories in Specimens From the North Central Cancer Treatment Group N9831 Intergroup Adjuvant Trial. Breast Diseases: A Year Book Quarterly 18(1):66-67, 2007. e-Pub 2007.

Review Articles

1. Ding Q, Huo L, Peng Y, Yoon EC, Li Z, Sahin AA. Immunohistochemical Markers for Distinguishing Metastatic Breast Carcinoma from Other Common Malignancies: Update and Revisit. Semin Diagn Pathol 39(5):313-321, 2022. e-Pub 2022. PMID: 35461734.

Abstracts

1. Yam C, Patel M, Sun J, Adrada BE, Raghavendra AS, MS, Litton JK, Mouabbi JA, Nwosu-Iheme A, Saleem S, Moscol G, Wright MD, Buzdar A, Murthy RK, Korkut A, Valero V, Tripathy D, Moseley TW, Wei P, Huo L, M Rauch AG. Early On-treatment Tumor Volume Reduction Predicts Response to the KEYNOTE-522 Regimen in Early Stage Triple-negative Breast Cancer. American Society of Clinical Oncology Annual Meeting 43(16), 2025.
2. Nasser SA, Zhang J, Pathak TB, Smith GH, Shoffeitt LC, Madabhushi A, Huo L, Badve S, Corredor G, Li AX. HAI-Score, An Objective HER2 Artificial Intelligence Method for Accurate H-Score Estimation from IHC-Stained Breast Cancer Samples. American Society of Clinical Oncology Annual Meeting, 2025.
3. Wang L, Chen H, Fei A, Zhang YH, Middleton LP, Krishnamurthy S, Huo L, Sahin A, Ding Q. GATA3 and TRPS1 Expression in Follicular Dendritic Cell Sarcoma. The 114th Annual Meeting, United States and Canadian Academy of Pathology, 2025.
4. Alrohaibani A, Sweeney K, Krasniqi R, Ding Q, Huo L, Wu Y, Dhamne S, Luthra R, Lucas FS, Roy-Chowdhuri S, Routbort M, Patel K, Yang R, Arun B, Albarracin C, Chen H. ESR1 Mutated Advanced Breast Cancer: Clinicopathological and Molecular Characteristics. The 114th Annual Meeting ,United States and Canadian Academy of Pathology, 2025.
5. Krasniqi R, Singh P, Huo L. The utility of frozen section evaluation of sentinel lymph nodes in patients with Estrogen Receptor positive/HER2 negative breast cancer and clinically node-negative disease undergoing neoadjuvant chemotherapy. The 114th Annual Meeting, United States and Canadian Academy of Pathology, 2025.
6. Chen J, Gong, Kai M, Huo L, Woodward WA. Variation of CCR7 Immune Cell Receptor Expression by Nodal Burden in Patients with Invasive Breast Cancer. San Antonio Breast Cancer Symposium, 2024.
7. Pan X, Ercan C, Wang Z, Jr RB, Pinao Gonzales KB, Yam C, Huo L, Yuan Y. Al-Derived Tumor-Infiltrating Lymphocytes Enhance the Model with Baseline Stromal Tumor-Infiltrating Lymphocytes and Ki-67 in Predicting Pathologic Complete Response in an Early-Stage Triple-Negative Breast Cancer Prospective Trial. San Antonio Breast Cancer Symposium, 2024.
8. Wanis KN, So A, Glencer A, Goetz L, Sun S, Teshome M, Hwang R, Hunt K, Huo L, Singh P. The utility of frozen section diagnosis following neoadjuvant chemotherapy in patients with clinically node negative HER2-positive or triple negative breast cancer, 2024.
9. Sun H, Huo L, Sweeney KJ, Resetkova E, Chai D, Chen H, Albarracin CT, Wu Y, Ding Q. SMARCA4/BRG1 Deficiency in Breast Carcinoma by Immunohistochemistry Study, 2024.
10. Siegal GP, Harada S, Khoury K, Yalniz C, Huo L, Ding Q, Sahin A, Huang X. Predictive Biomarkers for Immune Checkpoint Inhibitor (ICI) and Poly (ADP-Ribose) Polymerase(PARP) Inhibitor (PARPi) in Advanced Stage Breast Carcinoma, 2024.
11. Li X, Lee JH, Gao Y, Zhang J, Bates KM, Rimm DL, Zhang H, Smith G, Lawson D, Meisel J, Chang J, Huo L. Immunohistochemistry Assays Cannot Differentiate HER2 Protein and RNA Levels in HER2-Low Breast Cancers and RNAscope Is A Promising Simple Assay to Quantify HER2 Expression, 2024.
12. Goetz L, Wanis K, So A, Glencer A, Singh P, Huo L. The utility of frozen section evaluation of sentinel lymph nodes in patients with triple-negative breast cancer and clinically node-negative disease undergoing neoadjuvant chemotherapy, 2024.
13. Li X, Lee J, Gao Y, Zhang J, Bates K, Rimm D, Zhang H, Smith GH, Lawson D, Meisel J, Chang J, Huo L. RNAScope: a practical approach and promising alternative to immunohistochemistry to quantify HER2 expression in breast cancer, 2023.
14. Rauch GM, Adrada BE, Guirguis MS, Patel MM, Candelaria RP, Mohamed MM, Moseley TW, Petross HTL, Leung WTJ, Whitman GJ, Lane D, Scoggins M, Perez F, Sun J, Pashapoor S, Xu Z, White JB, Wei P, Reed B, Bum Son J, Hwang KP, Panthi B, Korkut A, Huo L, Hunt KK, Clayborn A, Litton JK, Valero V, Tripathy D, Yang WT, Ma J, Yam C. Early prediction of response to Neoadjuvant Immunotherapy in Triple Negative Breast Cancer (TNBC) with DCE-MRI, 2023.
15. Xu Z, Pashapoor S, Panthi B, Son JB, Hwang KP, Adrada BE, Candelaria RP, Guirguis MS, Patel MM, Le- Petross HTC, Leung JWT, Scoggins ME, Whitman GJ, Mohamed RM, Lane DL, Moseley T, Perez F, White J, Ravenberg E, Clayborn A, Pagel MD, Chen H, Sun J, Wei P, Thompason A, Moulder S, Korkut A, Huo L, Hunt KK, Litton JK, Valero V, Tripathy D, Yang W, Yam C, Rauch GM, MA J. Tumor segmentation with nnU-Net on dynamic contrast enhanced MR images of triple negative breast cancer, 2023.
16. Panthi B, Pashapoor S, Adrada BE, Candelaria RP, Guirguis MS, Patel MM, Mohamed RM, Boge M, Zhou Z, Son JB, Hwang KP, Le-Petross HTC, Leung JWT, Scoggins ME, Whitman GJ, Xu Z, Lane DL, Moseley T, Perez F, White J, Ravenberg E, Clayborn A, Pagel MD, Chen H Sun J, Wei P, Thompson A, Moulder S, Korkut A, Huo L, Hunt KK, Litton JK, Valero V, Tripathy D, Yang W, Yam C, Rauch GM, MA J. Early Prediction of Response to Neoadjuvant Systemic Therapy of Triple Negative Breast Cancer using Radiomics on DCE-MRI, 2023.
17. Yan Y, Lin Y, Kumar T, Bai S, Li J, Tran T, Hu M, Ravenberg E, Rauch GM, Clayborn A, Thompson A, Lim B, Huo L, Moulder S, Yam C, Navin N. Decoding the natural biology and response to chemotherapy of triple-negative breast cancer with single-cell transcriptomics, 2023.
18. Bartow BB, Siegal GP, Huo L, Ding Q, Sahin AA, Harada S, Huang X. Mutations in Homologous Recombination Genes and Loss of Heterozygosity Status in Advanced Stage Breast Carcinoma, 2023.
19. Ye Q, Han C, Chen H, Sahin A, Huo L, Ding Q. Nuclear Staining for Pan-Trk by Immunohistochemistry Is Highly Specific for Secretory Carcinoma: Pan-Trk in Various Subtypes of Breast Carcinoma, 2023.
20. Chen H, Wu Y, Ding QQ, Huo L, Khazai L, Sahin A, Albarracin CT. HER2-low Breast Cancers: Comparison of HER2 Scores by Immunohistochemistry and Oncotype, 2023.
21. Batra H, Barrientos EN, Guo H, Huang X, Rasi MG, Ding QQ, Huo L. PD-L1 Expression by Immunohistochemistry: Comparison Between Tissue Microarrays and Whole Slide Sections in Breast Carcinoma, 2023.
22. Guirguis MS, Adrada BE, Patel M, Perez F, Candelaria RP, Sun J, Mohamed RM, Boge M, Le- Petross HT, Leung JW, Whitman GJ, Lane DL, Scoggins ME, Moseley T, Musall B, White J, Pashapoor S, Wei P, Son JB, Hwang KP, Panthi B, Huo L, Hunt K, Ravenberg E, Thompson A, Litton J, Valero V, Tripathy D, Moulder S, Yam C, Ma J, Yang WT, Rauch GM. DCE-MRI for Early Prediction of Excellent Response versus Chemoresistance in Triple Negative Breast Cancer, 2022. e-Pub 2022.
23. Yam C, Li Z, Korkut A, Ma W, Kong E, Hill HA, Abbas H, Abouharb S, Adrada B, Arun BK, Barcenas CH, Bisen A, Bosser D, Buzdar A, Candelaria RP, Chen JJ, Clayborn A, Damodaran S, Ding QQ, Garber H, Hortobagyi GN, Hunt KK, Ibrahim NK, Iheme A, Karuturi MS, Koenig K, Layman RM, Lee J, Litton JK, Mitchell M, Moscol G, Mouabbi J, Murthy RK, Oke O, Pohlmann P, Ramirez D, Ravenberg E, Saleem S, Teshome M, Valero V, White J, Williams M, Woodward WA, Yajima C, Ueno NT, Chen K, Rauch GM, Huo L, Tripathy D. Clinical and Molecular Characteristics of HER2-Low/Zero, Early Stage Triple-Negative Breast Cancer, 2022.
24. Panthi B, Mohamed RM, Pashapoor S, Adrada BE, Candelria RP, Guirguis MS, Boge M, Patel MM, Elshafeey N, Zhou Z, Son JB, Hwang KP, Le-Petross HTC, Leung JWT, Scoggins ME, Whitman GJ, Xu Z, Lane DL, Moseley T, Perez F, White J, Ravenberg E, Clayborn A, Chen H, Sun J, Wei P, Thompson A, Moulder S, Korkut A, Huo L, Hunt KK, Litton JK, Valero V, Tripathy D, Yang W, Yam C, Ma J, Rauch GM. Longitudinal Dynamic Contrast Enhanced (DCE)-MRI Radiomic Models for Early Prediction of Response to Neoadjuvant Systemic Therapy (NAST) in Triple Negative Breast Cancer, 2022.
25. Mohamed RM, Panthi B, Pashapoor S, Adrada BE, Candelaria RP, Guirguis MS, Boge M, Patel MM, Elshafeey N, Zhou Z, Son JB, Hwang KP, Le- Petross HTC, Leung JWT, Scoggins ME, Whitman GJ, Xu Z, Lane DL, Moseley T, Perez F, White J, Ravenberg E, Clayborn A, Chen H, Sun J, Wei P, Thompson A, Moulder S, Korkut A, Huo L, Hunt KK, Litton JK, Valero V, Tripathy D, Yang W, Yam C, Ma J, Rauch GM. Multi-Parametric MRI-Based Radiomics Models for Early Response Prediction of Neoadjuvant Systemic Treatment of Triple Negative Breast Cancer, 2022.
26. Guirguis MS, Adrada BE, Patel MM, Perez F, Candelaria RP, Yang W, Jun J, Mohamed RM, Boge M, Le-Petross HC, Leung JWT, Whitman GJ, Lane DL, Scoggins ME, Mosely TW, Musall B, White J, Zhou Z, Wei P, Son JB, Hwang KP, Panthi B, Pagel M, Huo L, Hunt K, Ravenberg E, thompson A, Litton J, Valero V, Tripathy D, Moulder S, Yam C, Ma J, Rauch GM. Early prediction of chemoresistance versus excellent response in triple negative breast cancer patients (TNBC) with DCE-MRI, 2022.
27. Adrada BE, Guirguis MS, Patel MM, Perez F, Candelaria RP, Yang W, Sun J, Mohamed RM, Boge M, Le-Petross HC, JWt L, Whitman GJ, Lane DL, Scoggins ME, Moseley T, Musall B, White J, Zhou Z, Wei P, Son JB, Hwang KP, Panthi B, Pagel M, Huo L, Hunt K, Ravenberg E, Thompson A, Litton J, Valero V, Tripathy D, Moulder S, Yam C, Ma J, Rauch GM. Development of a combined model for early prediction of pathologic complete response (pCR) in Triple Negative Breast Cancer (TNBC) undergoing neoadjuvant therapy (NAT), 2022.
28. Yoon EC, Huo L, Gan Q, Middleton LP, Sahin A, Ding Q. Expression of TRPS1, SOX10 and GATA3 in Different Subtypes of Metaplastic Breast Carcinoma, 2022.
29. Sweeney KJ, Wang J, Albarracin CT, Roy-Chowdhuri S, Patel KP, Routbort M, Ding Q, Wu Y, Huo L, Sahin AA, Luthra R, Chen H. PTEN Alterations in Advanced ER+ Breast Cancer: Correlation with Clinicopathologic and Molecular Features, 2022.
30. Rauch GM, Candelaria RP, Guirguis MS, Boge M, Mohamed RMM, Elshafeey N, Sun J, Whitman GJ, Leung JJ, Le-Petross HC, Santiago L, Lane D, Scoggins M, Spak D, Patel MM, Perez F, White JB, Ravenberg E, Peng W, Tripathy D, Valero V, Litton J, Huo L, Yam C, Thompson, Ma J, Moulder SL, Yang W, Adrada BE. Integrated model for early prediction of neoadjuvant systemic therapy response in Triple Negative Breast Cancer, 2021.
31. Wu C, Jarrett AM, Zhou Z, Elshafeery N, Adrada BE, Candelaria RP, Mohamed R, Boge M, Huo L, White J, Tripathy D, Valero V, Litton J, Yam C, Son JB, Ma J, Rauch GM, Yankeelov TE. Forecasting treatment response to neoadjuvant systemic therapy in triple negative breast cancer via mathematical modeling and quantitative MRI, 2021.
32. Guirguis MS, Adrada BE, Candelaria RP, Sun J, Whitman GJ, Wt Y, Boge M, Mohamed RM, Elshafeey NA, Lane DL, Le-Petross H, JWt L, Santigao L, Scoggins ME, Spak DA, Patel M, Perez F, Wei P, Tripathy D, White J, Ravenberg E, Huo L, Litton J, Arun B, Valero, V, Thompson A, Moulder S, Yam C, Rauch GM. Prediction of response to neoadjuvant systemic therapy in triple negative breast cancer using baseline tumor MRI characteristics and imaging patterns of response, 2021.
33. Rauch GM, Candelaria RP, Guirguis MS, Elshafeey NA, Sun J, Yang W, Boge M, Mohamed RM, Whitman GJ, Dl L, Le-Ptross HC, Leung JWT, Santiago L, Scoggins ME, Spak DA, Patel MM, Perrez F, Musall B, White J, Wei P, Zhou Z, Pagel M, Ma J, Ravenberg E, Thompson A, Huo L, Litton J, Valero V, Tripathy D, Yam C, Moulder S, Adrada BE. A composite model for pathologic complete response (pCR) prediction in Triple Negative Breast Cancer (TNBC), 2021.
34. Rauch GM, Guirguis MS, Candelaria RP, Elshafeey NA, Sun J, Yang W, Boge M, Mohamed RM, Whitman GJ, Lane DL, Le-Petross HC, Leung JWT, Santiago L, Scoggins ME, Spak DA, Patel MM, Perez F, Musall B, White J, Zhou Z, Wei, P, Pagel M, Ma J, Damodaran S, Huo L, Ravenberg E, Thompson A, Litton J, Valero V, Tripathy D, Yam C, Moulder S, Adrada BE. Early prediction of chemoresistance versus excellent response in triple negative breast cancer patients (TNBC) with DCE-MRI, 2021.
35. Abuhadra N, Chang C, Yam C, White JB, Ravenberg E, Lim B, Ueno NT, Litton JK, Arun B, Domadaran S, Murthy RK, Ibrahim NK, Hortobagyi GN, Valero V, Tripathy D, Thompson AM, Mittendorf EA, Huo L, Moulder SL, Jenq RR. The impact of gut microbial composition on response to neoadjuvant chemotherapy (NACT) in early-stage triple negative breast cancer (TNBC), 2021.
36. Yam C, Mittendorf EA, Sun R, Huo L, Damodaran S, Rauch GM, Candelatia RP, Adrada BE, Seth S, Symmans WF, Murthy RK, White JB, Ravenburg E, Clayborn A, Prabhakaran S, Valero V, Thompson AM, Tripathy D, Moulder SL, Litton JK. Neoadjuvant atezolizumab (atezo) and nab-paclitaxel (nab-p) in patients (pts) with triple-negative breast cancer (TNBC) with suboptimal clinical response to doxorubicin and cyclophosphamide (AC), 2021.
37. Wang J, Albarracin CT, Huo L, Ding Q, Wu Y, Roy-Chowdhuri S, Patel KP, Routbort M, Luthra R, Chen H. PTEN Alteration in ER+ Breast Cancer: Correlative Study of Immunohistochemistry and Next Generation Sequencing, 2021.
38. Ai D, Sweeny KJ, Chen H, Huo L, Wu Y, Resetkova E, Yoon EC, Wang WL, Albarracin CT. ER-/PR+ Breast Cancer Cases Across Two FDA-Approved Platforms: Incidence and Clinicopathologic Correlates, 2021.
39. Abuhadra N, Yam C, Sun R, Huo L, Litton JK, Thompson AM, Lim B, Adrada B, Mittendorf E, Damodaran S, White J, Ravenberg E, Arun B, Ueno N, Murthy RK, Ibrahim N, Sahin A, Lucci A, Tripathy D, Valero V, Hortobagyi G, Moulder S, Chang J. Prospective evaluation of patients with metaplastic (Mp) triple negative breast cancer (TNBC): molecular characteristics and outcomes with neoadjuvant therapy (NAT), 2020.
40. Elshafeey NA, Adrada BE, Candelaria RP, Abdelhafez AH, Musall BC, Sun J, Boge M, Mohammed RMM, Mahmoud HS, Son JB, Kotrouso A, Zhang, S, Leung J, Lane D, Scoggins M, Spak D, Arribas E, Santiago L, Whitman GJ, Le-Petros HT, Moseley TW, White JB, Ravenberg E, Hwang KP, Peng W, Litton J, Huo L, Tripathy D, Valero V, Thompson AM, Moulder S, Yang WT, Pagel MD, Ma J, Rauch GM. Radiomic phenotypes from Dynamic Contrast-Enhanced MRI (DCE-MRI) parametric maps for early prediction of response to neoadjuvant systemic therapy (NAST) in Triple Negative Breast Cancer (TNBC) patients, 2020.
41. Rauch GM, Adrada BE, Candelaria RP, Elshafeey NA, Abdelhafez AH, Musall BC, Sun J, Boge M, Mohamed RMM, Son J, Zhang S, Leung J, Lane D, Scoggins M, Spak D, Arribas E, Santiago L, Whitman GJ, Le-Petross HT, Moseley TW, White JB, Ravenberg E, Hwang K, Peng W, Huo L, Litton JK, Valero V, Tripathy D, Thompson AM, Pagel MD, Ma J, Yang WT, Moulder S. Volumetric changes on longitudinal Dynamic Contrast Enhanced (DCE-MRI) as an early treatment response predictor to Neoadjuvant Systemic Therapy (NAST) in Triple Negative Breast Cancer (TNBC) Patients, 2020.
42. Seth S, Rauch G, Adrada B, Piwnica-Worms H, Huo L, Thompson A, Symmans W, Lim B, White J, Draette GF, Futreal A, Chang J, Moulder S. A tiered algorithm using mid-therapy ultrasound (US) response assessment and a novel gene expression signature (GES) improves the prediction of pathologic complete response (pCR) to neoadjuvant therapy (NAT) in triple-negative breast cancer (TNBC): Results from the ARTEMIS trial (NCT02276443), 2020.
43. Abuhadra N, Sun R, Litton JK, RauchGM, Thompson AM, Lim B, Adrada BE, Mittendorf EA, White JB, Ravenberg E, Damodaran S, Candelaria RP, Arun B, Ueno NT, Santiago L, Murthy RK, Ibrahim NK, Symmans WF, Moulder SL, Huo L. Prognostic impact of high stromal tumor-infiltrating lymphocytes (sTIL) in the absence of pathologic complete response (pCR) to neoadjuvant therapy (NAT) in early stage triple negative breast cancer (TNBC), 2020.
44. Lim B, Seth S, Huo L, Layman RM, Valero V, Thompson AM, White JB, Litton JK, Damodaran S, Candelaria RP, Arun B, Rauch GM, Murthy RK, Ding Q, Symmans WF, Zhao L, Zhang J, Tripathy D, Moulder SL, Ueno NT. Comprehensive profiling of androgen receptor–positive (AR+) triple-negative breast cancer (TNBC) patients (pts) treated with standard neoadjuvant therapy (NAT) +/- enzalutamide, 2020.
45. Basho RK, Yam C, White JB, Zhao L, Huo L, Mittendorf EA, Thompson AM, Litton JK, Arun B, Lim B, Valero V, Tripathy D, Zhang J, Adrada BE, Santiago L, Ravenberg E, Moulder SL, Damodaran S. Incidence of PI3K pathway alteration and response to neoadjuvant therapy (NAT) in triple negative breast cancer (TNBC) subtypes, 2020.
46. Moulder S, Bassett RL, White JB, Huo L, Damodaran S, Lim B, Ueno NT, Krishnamurthy R, Arun B, Valero V, Tripathy D, Hortobagyi GN, Litton JK, Thompson AM, Mittendorf EA, Ravenberg E, Santiago L, Adrada BE, Candelaria RP, Rauch GM. Statistical modeling of a novel clinical trial design using neoadjuvant therapy (NAT) to personalize therapy in patients (pts) with triple negative breast cancer (TNBC), 2020.
47. Huang X, Ding Q, Guo H, Sui D, Gong Y, Wu Y, Wang W, Huo L. Comparison of Three FDA Approved PD-L1 Immunohistochemistry Assays in Triple Negative Breast Carcinoma, 2020.
48. Chen H, Hou T, Huo L, Wu Y, Wang W, Albarracin CT. Significance of ER-/PR+ Breast Cancer Cases: Re-evaluation of Biomarker Status and Clinical Correlates, 2020.
49. Yam C, Alatrash G, Yen E, Garber H, Philips AV, Huo L, Yang F, Bassett Jr RL, Sun X, Cuentas ERP, Symmans WF, Seth S, White JB, Rauch GM, Damodaran S, Litton JK, Wargo JA, Hortobagyi GN, Moulder SL, Mittendorf EA. Immune phenotype and response to neoadjuvant systemic therapy (NAST) in triple negative breast cancer (TNBC), 2020.
50. Abuhadra N, Hess KR, Litton JK, Rauch GM, Am T, Lim B, Adrada B, White J, Ravenburg EE, Mittendorf E, Damodaran S, Candelaria R, Arun B, Yang WT, Ueono N, Santiago L, Murthy RK, Ibrahim N, Sahin AA, Symmans WF, Moulder SL, Huo L. Serial TILs: Evaluating the role of mid-treatment stromal tumor infiltrating lymphocytes (TILs) in predicting pathologic complete response (pCR) in early-stage triple negative breast cancer (TNBC), 2019.
51. Villodre ES, Hu X, Gong Y, Song J, Larson R, Eckhardt BL, Huo L, Krisnamurthy S, Ibrahim N, Uemuno NT, Tripathy D, Woodward WA, Debeb BG. NDRG1-EGFR axis in inflammatory breast cancer tumorigenesis and brain metastasis, 2019.
52. Abuhadra N, Hess KR, Litton JK, Rauch GM, Am T, Lim B, Adrada B, Mittendorf E, Damodaran S, Candelaria R, Arun B, Yang WT, Ueno N, Santiago L, Murthy RK, Ibrahim N, Sahin AA, Symmans WF, Moulder SL, Huo L. Beyond TILs: Predictors of pathologic complete response (pCR) in triple-negative breast cancer (TNBC) patients with moderate tumor infiltrating lymphocytes (TIL) receiving neoadjuvant therapy, 2019.
53. Seth S, Huo L, Raunch GM, Adrada BE, Piwnica-Worms H, Thompson AM, Mitendorf EA, Litton JK, Symmans WF, Draetta GF, Futreal A, Moulder SL, Chang J. Delineating longitudinal patterns of response to neoadjuvant systemic therapy (NAST) in triple-negative breast cancer (TNBC): Profiling results from a randomized, TNBC enrolling trial to confirm molecular profiling improves survival (ARTEMIS; NCT02276443), 2019.
54. Seth S, Crespo J, Huo L, Thompson AM, Mittendorf EA, Hess KR, Litton JK, Rauch GM, Adrada BE, Damodaran S, Candelaria RP, Arun B, Yang WT, Santiago L, Murthy RK, Sahin AA, Symmans WF, Moulder SL, Ueno NT, Lim B. Evaluation of predictive biomarkers for AR therapy and to identify the LAR subtype of TNBC, 2019.
55. Crespo J, Seth S, Ravenburg E, Huo L, Hess K, Santiago L, Adrada B, Raunch G, Senthil D, Murthy R, Litton J, Tripathy D, Ueno NT, Moulder SL, Lim B. Characterization of the LAR-subtype triple-negative breast cancer population, 2019.
56. Yam C, Raghavendra A, Hess KR, Adrada BE, Candelaria RP, Demodaran S, Gilcrease MZ, Helgason T, Hortobagyi GN, Huo L, Layman RM, Lim B, Litton JK, Mittendorf EA, Murthy RK, Piwinca-Worms H, Rauch GM, Santiago L, Symmans WF, Thompson AM, Tripathy D, Ueno NT, Valero V, Barcenas CH, Moulder SL, Yang W. Impact of Serial Biopsies in Triple-Negative Breast Cancer Patients Receiving Neoadjuvant Systemic Therapy, 2018.
57. Moulder S, Hess KS, Candelaria R, Rauch GM, Santiago L, Adrada B, Yang WT, Gilcrease M, Huo L, Stauder MC, Arun B, Layman R, Murthy RK, Damodaran SD, Ueno S, Thompson AM, Lim B, Mittendorf E, Litton JK, Symmans WF. Precision neoadjuvant therapy (P-NAT): a planned interim analysis of a randomized, TNBC Enrolling trial to confirm Molecular profiling Improves Survival (ARTEMIS), 2018.
58. Guo H, Ding Q, Gong Y, Gilcrease MZ, Zhao M, Zhao J, Wu Y, Chen H, Moulder SL, Wang W, Huo L. PD-L1 expression (clone 28-8) and tumor infiltrating lymphocytes in primary invasive breast cancer, 2018.
59. Abbott SE, Broaddus R, Huo L, Albarracin C, Routbort MJ, Luthra R, Patel KP, Chen H. ESR1 somatic mutation analysis in advanced breast cancer: Correlation with clinicopathologic and molecular features, 2018.
60. Guo H, Ding Q, Gong Y, Gilcrease MZ, Zhao M, Zhao J, Wu Y, Chen H, Moulder SL, Wang L, Huo L. PD-L1 expression (clone 22c3) and tumor infiltrating lymphocytes in primary invasive breast cancer, 2018.
61. Shen T, Zhao J, Zhao M, Taggart MW, Ramalingam P, Gong Y, Wu Y, Huo L. Unusual expression of immunohistochemical markers PAX8 and CDX2 in breast cancer, 2018.
62. Yam C, Huo L, Hess K, Litton J, Yang W, Piwnica-Worms H, Mittendorf EA, Ueno NT, Lim B, Murthy RK, Damodaran S, Helgason T, Thompson AM, Santiago L, Candelaria RP, Rauch GM, Adrada BE, Symmans WF, Gilcrease MZ, Moulder SL. Androgen receptor positivity is associated with nodal disease in triple negative breast cancer, 2017.
63. Yam C, Santiago L, Candelaria RP, Adrada BE, Rauch GM, Hess KR, Litton JK, Piwnica-Worms H, Mittendorf EA, Ueno NT, Lim B, Murthy RK, Damodaran S, Helgason T, Huo L, Thompson AM, Gilcrease MZ, Symmans WF, Moulder SL, Yang W. Risk of needle-track seeding with serial ultrasound-guided biopsies in triple negative breast cancer, 2017.
64. Zhao J, Lu X, Zhang M, Guo C, Huo L, Yemelyanova A, Navai N, Broaddus R, Chen H. Integration of HER2 Overexpression/amplification with molecular mutation profile in urothelial carcinoma, 2017.
65. Chen H, Sahin AA, Lu X, Huo L, Singh RR, Abraham R, Virani S, Mishra BM, Broaddus R, Luthra R. Assessment of breast cancer with borderline HER2 status using MIP microarray, 2017.
66. Tsai JW, Huo L, Khan S, Wani K, Lazar AJ, Wang WL. Primary breast sarcomas: Clinico-pathological study of 16 cases, 2017.
67. Li X, Yang J, Peng L, Sahin A, Huo L, Ward KC, O’Regan R, Torres MA, Meisel JL. Triple negative breast cancer has worse overall survival and cause-specific survival than non-triple negative breast cancer, 2017.
68. Dai A, Lin K, Jr BR, Huo L, Sahin A, Lu X, Chen H. Amplification of FGFR1 gene and associated chromothripsis-like pattern in breast cancer, 2016.
69. Lin K, Dai A, Huo L, Sahin A, Wu Y, Lu X. Chromothripsis-like pattern in chromosome 17q12 is associated with HER2 amplification in breast cancer, 2016.
70. Ding Q, Wang Y, Zuo Z, Ueno N, Wei W, Huo L. Decreased expression of miR-26b in advanced breast cancer, 2016.
71. Li X, Krisnamurti U, Huo L, Peng L. Male breast carcinoma has worse prognosis than female breast carcinoma, 2016.
72. Chen H, Lu X, Singh R, Huo L, Bousamra A, Abraham R, Virani S, Mehrotra M, Mishra B, Roy-Chowdhuri S, Routbort M, Kenneth A, Broaddus R, Yao H, Sahin A, Patel KP, Luthra R. Quantitative assessment of ESR, PGR, and genome-wide copy number aberrations in advanced breast cancer by SNP Microarray, 2015.
73. Vila J, Mittendorf EA, Basset RL, Bedrosian I, Shaitelman SF, Stauder, MC, Chavez-McGregor M, Litton JF, Yang WT, Huo L, Kuerer HM, Hunt KK, Caudle AS. A nomogram to predict axillary response to neoadjuvant chemotherapy in clinically node positive breast cancer patients, 2015.
74. Chen H, Singh RR, Huo L, Lu X, Bousamra A, Abraham R, Mehrotra M, Mishra BM, Virani S, Roy-Chowdhuri S, Routbort M, Aldape K, Broaddus R, Sahin A, Patel KP, Luthra R. FGFR1 and EGFR amplification in breast cancer, 2015.
75. Debeb BG, Lacerda L, Anfossi S, Diagaradjane P, Chu K, Huo L, Wei C, Larson RA, Wolfe AR, Xu W, Smith DL, Li L, Ivan C, Allen PK, Zhang XH, Calin GA, Krishnamurthy S, Ueno NT, Buchholz TA, Reuben JM, and Woodward WA. The microRNA miR-141 is a key regulator of brain metastasis from breast cancer, 2014.
76. Anfossi S, Giordano A, Huo L, Alvarez RH, Valero V, Hortobagyi GN, Woodward WA, Ueno NT, Calin GA, Reuben JM. High miR-19a serum levels are prognostic of favorable clinical outcome in patients with metastatic HER2+ inflammatory breast cancer may derive from an effective antibody-dependent cell-mediated cytotoxicity induced by trastuzumab, 2014.
77. Chen H, Broaddus R, Huo L, Zhang M, Guo C, Robinson M, Trivedi S, Fernandez R, Navai N, Lu X. Examination of HER2 overexpression and amplification in urothelial carcinoma with micropapillary features using ASCO/CAP 2013 guideline, 2014.
78. Debeb BG, Lacerda L, Anfossi S, Diagaradjane P, Chu K, Huo L, Wei C, Larson RA, Wolfe AR, Xu W, Smith DL, Li L, Ivan C, Allen PK, Zhang XH, Calin GA, Krishnamurthy S, Ueno NT, Buchholz TA, Reuben JM, and Woodward WA. The microRNA miR-141 is a key regulator of brain metastasis from breast cancer, 2014.
79. Lee SM, Huo L, Lazar AJ, Wang WL. MYC expression in mammary vascular tumors, 2014.
80. Lee SM, Huo L, Lazar AJ, Wang WL. C-MYC expression in sporadic and radiation-associated sarcomas, 2014.
81. Debeb BG, Lacerda L, Li L, Larson R, Xu W, Huo L, Wei C, Reuben JM, Ueno NT, Buchholz TA, Woodward WA. The miR-200 family as a potential therapeutic target in inflammatory breast cancer, 2013.
82. Li X, Huo L, Moulder SL, Gilcrease MZ. Analysis of gene mutations in subtypes of metaplastic carcinoma of the breast, 2013.
83. Gong Y, Wei W, Wu Y, Huo L. Expression of androgen receptor in triple-negative breast carcinomas and inflammatory breast carcinomas, 2013.
84. Yi M, Huo L, Koenig K, Mittendorf EA, Meric-Bernstam F, Kuerer HM, Bedrosian I, Symmans WF, Crow JR, Shah RR, Hortobagyi GN, Hunt KK. Estrogen receptor positivity: 10% or 1%?, 2012.
85. Debeb BG, Lacerda L, Larson R, Li L, Xu W, Huo L, Wei C, Krishnamurthy S, Reuben JM, Ueno NT, Buchholz TA, Woodward WA. The miR-200 family as a potential therapeutic target in inflammatory breast cancer, 2012.
86. Alvarez R, Cristofanilli M, Ensor J, Lucci A, Yang WT, Le-Petross HT, Reuben JM, Babiera G, Huo L, Gong Y, Woodward WA, Parker CA, Willey JS, Buchholz TA, Ueno MT, Valero V. Limited efficacy and significant toxicities of lapatinib (Lap) plus chemotherapy as neoadjuvant therapy (NAC) for HER2-positive inflammatory breast cancer (IBC) patients (Pts), 2012.
87. Akay CL, Ueno NT, Chisholm GB, Hortobagyi GN Woodward WA, Alvarez RH, Lucci A, Bedrosian I, Kuerer HM, Hunt K, Huo L, Babiera G. Primary tumor resection to improve survival and local disease control in stage IV inflammatory breast cancer, 2012.
88. Li X, Deavers MT, Guo M, Middleton L, Liu P, Huo L. The effect of prolonged cold ischemia time on estrogen receptor detection in breast cancer, 2012.
89. Debeb BG, Lacerda L, Anfossi A, Diagaradjane P, Chu K, Huo L, Wei C, Larson RA, Wolfe AR, Xu W, Smith DL, Li L, Ivan C, Allen PK, Zhang XH, Calin GA, Krishnamurthy S, Ueno NT, Buchholz TA, Reuben JM, and Woodward WA. The microRNA miR-141 is a key regulator of brain metastasis from breast cancer, 2011.
90. Yam C, Mittendorf EA, Sun R, Huo L, Damodaran S, Rauch GM, Candelatia RP, Adrada BE, Seth S, Symmans WF, Murthy RK, White JB, Ravenburg E, Clayborn A, Prabhakaran S, Valero V, Thompson AM, Tripathy D, Moulder SL, Litton JK. Neoadjuvant atezolizumab (atezo) and nab-paclitaxel (nab-p) in patients (pts) with triple-negative breast cancer (TNBC) with suboptimal clinical response to doxorubicin and cyclophosphamide (AC), 2011.
91. Nayak A, Gilcrease MZ, Middleton LP, Carkaci S, Zhang J, Sneige N, Huo L. Papillomas on core needle biopsy: analysis of 88 cases, 2011.
92. Lane D, Arribas E, Resetkova E, Huo L, Yang W. The significance of residual mammographic calcifications after neoadjuvant therapy, 2010.
93. Gong Y, Huo L, Sneige N, Cristofanilli M. Positive expression of enhancer of zeste homolog 2 (EZH2) predicts shorter overall survival in patients with inflammatory breast cancer, 2010.
94. Lester TR, Arun BK, Gutierrez Barrera A, Huo L, Albarracin CT, Gilcrease MZ. Triple-negative phenotype and/or high mitotic rate may improve selection of high-risk patients for BRCA testing, 2010.
95. Huo L. Correlation of apocrine DCIS on core needle biopsy with excision, 2010.
96. Wei B, Tian Z, Tang F, Wei W, Milcrease MZ, Huo L, Albarracin CT, Resetkova E, Middleton LP, Sahin A, Chen J, Abraham SC. Prognostic factors of primary invasive mammary neuroendocrine carcinoma: clinicopathologic analysis of 74 cases, 2010.
97. Tang F, Gilcrease MZ, Albarracin CT, Huo L, Middleton LP, Resetkova E, Wu Y. Invasive solid papillary carcinoma of the breast: a clinicopathologic analysis of 52 cases, 2008.
98. Nguyen CV, Deavers MT, Quinones J, Huo L. Estrogen receptor immunohistochemistry for confirmation of sentinel lymph node metastasis in cases with equivocal cytokeratin positivity, 2008.
99. Huo L, Resetkova E, Lopez A, Sneige N. Sentinel lymph node (SLN) sampling in patients with core biopsy diagnosis of ductal carcinoma in situ (DCIS): UT M.D. Anderson cancer caner experience and future recommendations, 2006.
100. Huo L, Wu Y, Meric-Bernstam F, Sahin AA. Morphologic features of ipsilateral recurrent breast cancers in patients treated with breast conserving therapy (BCT), 2005.
101. Huo L, Kashireddy P, Rao MS, Diaz LK. Peroxisome proliferator-activated receptor gamma expression in invasive breast cancer, 2004.
102. Diaz LK, Huo L, Gupta A, Kidwai N, Sneige N, Wiley EL. Comparison of the effects of alcoholic formalin fixation to standard formalin fixation on estrogen receptor analysis by immunohistochemistry in breast cancer, 2004.
103. Huo L, Patton KT, Adley BP, Gupta R, Papavero V, Laskin WB, Yeldandi A, Yang XJ. Analysis of c-kit expression in 171 renal neoplasms, 2004.
104. Diaz LK, Huo L, Herm J, Clatch R. Rapid and low cost image analysis for tissue microarray immunohistochemistry, 2004.
105. Huo L, Adley BP, Patton KT, Sugimura J, Teh BT, Yang XJ. Comparison of c-kit expression in chromophobe renal cell carcinoma and renal oncocytoma, 2004.
106. Chuang ST, Gupta A, Huo L, Keh P, Rao MS. Comparative analysis of cell cycle regulatory proteins and cell adhesion molecules in endometrioid adenocarcinomas and serous papillary carcinomas of the ovary, 2003.

Book Chapters

1. Huo L, Albarracin CT, Sneige N. Immunological and Molecular Studies in Breast Tumors. In: Immunological and Molecular Diagnosis of Cancer. Nova Science Publishers, 209-244, 2011.

Letters to the Editor

1. Villodre ES, Hu X, Huo L, Debeb BG. Response to de Nonneville, Finetti, Mamessier and Bertucci. J Natl Cancer Inst 114: 1048-1049, 2022.
2. Albarracin C, Edgerton ME, Gilcrease MZ, Huo L, Krishnamurthy S, Middleton LP, Resetkova E, Sahin AA, Sneige N, Fraser WS, Wu Y. Is it too soon to start reporting HER2 genetic heterogeneity?. Arch Pathol Lab Med 134: 162-3; author reply 163, 2010.